-
CStone's platinib enters China for approval and is expected to usher in the first approved RET inhibitor
Time of Update: 2021-04-28
Public information shows that the indication for this application of the drug is a locally advanced or metastatic non-small cell lung cancer (NSCLC) adult patient who has previously received platinum-containing chemotherapy and has a positive RET gene fusion.
-
A rout ten years ago drove domestic HPLC out of mainstream pharmaceutical companies
Time of Update: 2021-04-28
If you want to choose the most important detection equipment in a pharmaceutical company, it may be high-performance liquid chromatography (HPLC).
However, a rout ten years ago brought everything to an abrupt end, and domestic HPLC was driven out of mainstream pharmaceutical companies.
-
Enhua Pharmaceutical's Class 1 chemical drug NH102 hydrochloride tablets was approved for clinical use
Time of Update: 2021-04-28
On March 15th, Enhua Pharmaceuticals issued an announcement stating that it had recently received the "Drug Clinical Trial Approval Notice" for 3 specifications of NH102 Hydrochloride Tablets, a category 1 chemical drug approved and issued by NMPA, and will start clinical trials in the near future .
-
The first domestic innovative preparation of ropivacaine multivesicular liposome is about to enter the clinic
Time of Update: 2021-04-28
Luye Pharmaceutical Group announced that the clinical trial application of its independently developed innovative preparation-Ropivacaine Hydrochloride Liposome Suspension Injection (LY09606) has been accepted by the Drug Evaluation Center of the National Medical Products Administration and will soon enter the clinical stage .
-
Tylenol Microlab TNM002 monoclonal antibody successfully obtained IND approval from the US FDA
Time of Update: 2021-04-28
, referred to as “Tinomab” and “Trinomab”) announced its self-developed recombinant anti-tetanus toxin monoclonal antibody drug TNM002 Its clinical trial application (IND) was officially approved by the U.
TNM002 is a natural and fully human monoclonal antibody drug developed by Trinomab using its HitmAb® technology platform with independent intellectual property rights.
-
Yangtze River Health: The State Food and Drug Administration agrees to change the holder of the marketing license for caspofungin acetate for injection
Time of Update: 2021-04-28
On March 18, the Yangtze River Health announced that the State Food and Drug Administration agreed that caspofungin acetate for injection (drug approval number: Sinopharm Zhunzi H202003001, Sinopharm Zhunzi H202003002, specifications 50mg, 70mg) drug marketing license holders "Borui Pharmaceutical (Suzhou) Co.
-
Donge Ejiao issued an announcement on the salary adjustment of the company's senior management
Time of Update: 2021-04-28
Strategic incentives account for 40% of the target's total cash compensation, and are dually related to the company's medium and long-term business performance and personal performance appraisal results.
137 million yuan/person; the total strategic incentives for the past three years are 13.
-
The pharmacy selling this health product was sent to trial for prosecution or sentenced for it
Time of Update: 2021-04-28
According to reports, in June 2020, the Xiejiaji Branch of the Huainan Public Security Bureau filed and investigated the suspected sale of toxic and harmful health food in a pharmacy in Xiejiaji based on the clues transferred by the district market supervision bureau.
-
Roche withdraws PD-L1 inhibitor Tecentriq for bladder cancer indications in the U.S.
Time of Update: 2021-04-28
As of July 2018, the data detection committee of the IMvigor130 study found that newly-treated locally advanced or metastatic urothelial cancer patients who were not suitable for cisplatin chemotherapy received Tecentriq single-agent first-line treatment, and patients with low PD-L1 expression survived As a result, the FDA has restricted Tecentriq's first-line treatment of bladder cancer as a restriction on the positive expression of PD-L1.
-
Indian Prime Minister Modi vaccinated the first dose of the new crown vaccine, which was developed locally in India
Time of Update: 2021-04-28
Modi said that through the efforts of Indian doctors and scientists, India was able to quickly develop a vaccine and strongly supported the global fight against the new crown pneumonia epidemic.
-
Lingkang Pharmaceutical's Ceftizoxime Sodium for Injection Received "Drug Registration Approval"
Time of Update: 2021-04-28
On June 14, 2012, Meida Pharm submitted its first domestic drug registration application to the State Food and Drug Administration for ceftizoxime sodium for injection and was accepted.
-
Why is there little news about the gradual launch of new crown vaccines?
Time of Update: 2021-04-28
From the end of 2020 to the present for more than two months, a variety of new crown vaccines have been approved for marketing worldwide, and large-scale vaccination has begun in China, the United States, Russia, Brazil, Southeast Asia, the Middle East and other countries and regions for the global economy and society The restoration of order brought dawn.
-
The latest announcement of Gansu Provincial Food and Drug Administration is related to enterprises and scientific research institutes inside and outside the province!
Time of Update: 2021-04-28
On March 22, the Gansu Provincial Food and Drug Administration issued a document to encourage enterprises and scientific research institutes inside and outside the province to participate in the formu
-
Novo Nordisk launches clinical trials of long-acting insulin in China once a week
Time of Update: 2021-04-28
The latest announcement of the Chinese drug clinical trial registration and information disclosure platform, Novo Nordisk launched a trial in China to study the pharmacokinetic characteristics of icodec insulin in Chinese subjects with type 2 diabetes, aiming to evaluate icodec insulin injections The stay and changes in the patient’s blood over time after administration.
-
Hengrui Medicine's carmustine for injection was approved by the U.S. FDA
Time of Update: 2021-04-28
Carmustine for injection was first developed by EMCURE PHARMACEUTICALS LTD and was approved in the United States in 1977 under the trade name BICNU.
After inquiries, there are currently 4 foreign companies that have approved generic carmustine for injection on the market.
-
Market | Rising stars are rising, the CDK4/6 inhibitor market is getting bigger and bigger
Time of Update: 2021-04-28
However, the latest overall survival (OS) of the Phase III MONALEESA-7 study of Kisqali combined with endocrine therapy for breast cancer is close to 5 years (58.
However, Ibrance combined with endocrine therapy in the treatment of HR+/HER2-early breast cancer in two phase III clinical studies, PALLAS and PENELOPE-B, suffered Waterloo.
-
The first in China! Idea Di AXL Inhibitor Application for Clinical
Time of Update: 2021-04-28
The advantage of AVB-500 is that it has a high affinity for GAS6 ligand, which solves the problem of low selectivity of TKI inhibitors targeting AXL, resulting in off-target toxicity, tumor cell resistance, and low affinity of monoclonal antibodies.
Previously, AVB-500 has shown potential efficacy in a phase Ib clinical trial for patients with platinum-resistant ovarian cancer (PROC).
-
FDA extends the review period for supplementary new drug applications for AbbVie RINVOQ due to safety considerations
Time of Update: 2021-04-28
CompileLiLiOn March 17, according to foreign media reports, AbbVie announced that the US FDA has extended the review period for the anti-inflammatory drug RINVOQ Supplemental New Drug Application (sNDA) for the treatment of active psoriatic arthritis (PsA) in adults.
-
Hepatocarcinoma immune drug combination therapy: analysis of clinical research on two major approved and two major first-line drugs
Time of Update: 2021-04-28
B. Lenvatinib + Novoliumab: The study of Lenvatinib combined with Novoliumab in the first-line treatment of patients with unresectable liver cancer reported at the 2020ASCO-GI meeting showed According to the mRECIST standard evaluation, the total ORR was 76.
-
AstraZeneca's CLL drug Calquence is approved by NICE in the UK
Time of Update: 2021-04-28
CompilationFan DongdongA few days ago, the National Institute of Health and Clinical Optimization (NICE) decided to recommend AstraZeneca’s BTK inhibitor Calquence (Acalabrutinib) into the British National Health Service (NHS) for the treatment of certain adult chronic lymphocytic leukemia (CLL).
